Company Overview and News

1
The Chinese Blind Spot in U.S. Companies’ Financials - WSJ

2018-07-21 wsj
There’s a blind spot in U.S. regulators’ oversight of audit firms--and it could mean investors in companies like Walmart Inc., Pfizer Inc. and 3M Co. are vulnerable.
PFZ MTSI 500680 PFE PFIZER

2
Roche Takes Drug-Price Posturing to New Heights - Bloomberg

2018-07-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ NVS 500680 PFE PFIZER

2
Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy

2018-07-20 zacks
Merck (MRK - Free Report) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%. The company also said it would not increase the average net price of other medicines in its portfolio of products by more than the inflation rate, annually. Merck claims that it has been taking measures to reduce prices. It also said that, in 2017, net prices across Merck’s U.
VRX NVS PFE

11
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

2018-07-20 zacks
J&J (JNJ - Free Report) and Novartis (NVS - Free Report) ringed in the earnings season for the pharma space. Meanwhile, Pfizer (PFE - Free Report) and Lilly’s (LLY - Free Report) pain drug showed early positive results in a late-stage study. The FDA approved J&J’s latest HIV medicine Symtuza as well as label expansion of Pfizer’s prostate cancer drug Xtandi. In the wake of deeper political scrutiny over the high cost of prescription medicines, Novartis said it won’t raise U.
KDP NVS ABBV PFE ABBV ONCE

82
Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive

2018-07-20 seekingalpha
Discussion: Catalyst Biosciences (CBIO) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptacog alfa (activated) in patients with hemophilia A or B with inhibitors. One administered patient showed significant improvement in prevention of bleeding in the first 96 days. Two other patients are yet to complete the first 50 days of dosing to determine any significant improvement.
MBRX ADAP ENZ AZN KPTI OVID CTIC CTI LLY CLRBZ SNY CLRBW CBIO IMMU JNJ NVS CLRB PFE ATOS

34
My Dividend Growth Portfolio - Q2 2018 Summary

2018-07-19 seekingalpha
I believe that someone who writes about financial assets should share his main holdings with his readers.
LMT FB GD GIS TXN XOM TWX UTX GOOG KMB K TWC GOOGL AAPL KHC SBUX ABBV MSFT ADM OHI MMP PFE ABBV

2
Merck to Limit Drug-Price Increases, Cut Some Prices - WSJ

2018-07-19 wsj
Merck & Co. said Thursday it will cut U.S. list prices for several of its drugs including the hepatitis C treatment Zepatier, and the company pledged to limit future net price increases.
PFZ NVS 500680 PFE PFIZER

1
Merck lowers prices of some drugs after Trump calls out industry

2018-07-19 reuters
(Reuters) - Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a little-used hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.
PFZ 500680 PFE PFIZER

1
Merck lowers prices of some drugs after Trump calls out industry - Channel NewsAsia

2018-07-19 channelnewsasia
REUTERS: Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a little-used hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.
PFZ 500680 PFE PFIZER

83
Jane's June Dividend Increases And Income - Retirement Accounts

2018-07-19 seekingalpha
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO IRET.PR DUKH GD IRET.PRC TRV IRET.PRB MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM IRET.PRCL RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL

4
The Startup Selling Generic Viagra and Rogaine to the Instagram Crowd - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ TGT MSFT 500680 PFE PFIZER

2
IBM Beats on Q2 Earnings, z14 Mainframe Aids Top-Line Growth

2018-07-19 zacks
International Business Machines Corp (IBM - Free Report) reported second-quarter 2018 non-GAAP earnings of $3.08 per share, which beat the Zacks Consensus Estimate by a nickel. Earnings per share (EPS) increased 4.8% from the year-ago quarter. The year-over-year growth in EPS can be attributed to higher revenues (10 cents contribution), solid pre-tax margin operating leverage (20 cents contribution) and aggressive share buybacks (seven cents contribution).
IBM DB ADSK PFE HPE

17
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

2018-07-19 zacks
Pfizer Inc. (PFE - Free Report) and Eli Lilly and Company (LLY - Free Report) announced that their NGF inhibitor, tanezumab, met all co-primary endpoints in a phase III study evaluating it in patients with osteoarthritis (“OA”) pain.
REGN PFZ TEVJF TEVA TEVVF 500680 PFE PFIZER

52
Your Daily Pharma Scoop: Tonix Progresses, J&J Succeeds, Quidel Is Cleared

2018-07-19 seekingalpha
Tonix Pharmaceuticals receives fast track designation for TNX-102 SL for treatment of agitation in alzheimer’s disease
CSCWF NTLA IRWD QDEL OPK KOOL CRSP KOOLW EDIT JNJ SYK NUVA PFE

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to PFE / Pfizer, Inc. on message board site Silicon Investor.

PFE (Pfizer) How high will it go? Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFER: Preference Technologies Pfizer(PFE)
CUSIP: 717081103